Massachusetts is expected to gain 350 jobs from Pfizer (NYSE:[[ticker:PFE]]) as the world’s largest drugmaker restructures its global research and development activities to cut $1.5 billion in spending, the Boston Globe reports. New York-based Pfizer—which employs 2,300 workers at two research hubs in Cambridge and a facility in Andover it acquired through its 2009 buyout of Wyeth—will be cutting 100 jobs in the Boston area while adding 450 jobs here through the relocation of its neuroscience and cardiovascular metabolic research groups from Groton, CT, the Globe reports. The company is now looking for a new site to house those research operations in the Boston area.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
